The role of angiogenic biomarkers and uterine artery Doppler in pregnant women with systemic lupus erythematosus or antiphospholipid syndrome

2018 ◽  
Vol 11 ◽  
pp. 99-104 ◽  
Author(s):  
M.E. Rodríguez-Almaraz ◽  
I. Herraiz ◽  
P.I. Gómez-Arriaga ◽  
P. Vallejo ◽  
E. Gonzalo-Gil ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Pregnant Women ◽  
Antiphospholipid Syndrome ◽  
Lupus Erythematosus ◽  
Uterine Artery ◽  
Systemic Lupus ◽  
Uterine Artery Doppler ◽  
Angiogenic Biomarkers

The role of second trimester uterine artery Doppler in pregnancies with systemic lupus erythematosus

2015 ◽  
Vol 35 (5) ◽  
pp. 447-452 ◽  
Author(s):  
Giorgio Pagani ◽  
Rossella Reggia ◽  
Laura Andreoli ◽  
Federico Prefumo ◽  
Sonia Zatti ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Uterine Artery ◽  
Second Trimester ◽  
Systemic Lupus ◽  
Uterine Artery Doppler

Predictive Value of Uterine Artery Velocity Waveforms in Pregnancies Complicated by Systemic Lupus erythematosus and the Antiphospholipid Syndrome

1992 ◽  
Vol 7 (3-4) ◽  
pp. 195-202 ◽  
Author(s):  
Jean-Louis Benifla ◽  
Catherine Tchobroutsky ◽  
Michèle Uzan ◽  
Yvette Sultan ◽  
Bernard J. Weill ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Antiphospholipid Syndrome ◽  
Lupus Erythematosus ◽  
Predictive Value ◽  
Uterine Artery ◽  
Systemic Lupus

scholarly journals The Contribution of Drugs and Helicobacter pylori to Gastric Mucosa Changes in Patients with Systemic Lupus Erythematosus and Antiphospholipid Syndrome

2019 ◽  
Vol 2019 ◽  
pp. 1-18 ◽  
Author(s):  
Tatiana M. Reshetnyak ◽  
Irina A. Doroshkevich ◽  
Natalia V. Seredavkina ◽  
Evgeny L. Nasonov ◽  
Igor V. Maev ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Acetylsalicylic Acid ◽  
Antiphospholipid Syndrome ◽  
Lupus Erythematosus ◽  
Low Dose ◽  
Gastric Body ◽  
Systemic Lupus ◽  
Anti Inflammatory ◽  
H Pylori

Background. The nature and rate of gastric mucosal (GM) damage in systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) remain to be among the unsolved problems. Objective. To define the role of H. pylori and drugs in the development of GM damages in SLE and APS. Methods. A study was conducted on 85 patients with SLE and APS. All the patients underwent esophagogastroduodenoscopy with targeted biopsy of the mucosa of the gastric body and antrum. The presence of H. pylori in the gastric biopsy specimens was determined using polymerase chain reaction. Results. Endoscopic examination revealed that the patients with SLE and APS on admission had the following GM changes: antral gastritis (82.4%), erosions (24.7%), hemorrhages (8.2%), and pangastritis (8.2%). SLE and APS patients showed no direct correlation between the found GM damages and the presence of H. pylori. The use of glucocorticoid, low-dose acetylsalicylic acid, nonsteroidal anti-inflammatory drug, and anticoagulant in SLE and APS patients is accompanied by GM damage. Conclusion. There was no evidence of the role of H. pylori in GM damage in the SLE and APS patients. More frequent detection of H. pylori was observed in anticoagulants or low-dose acetylsalicylic acid users than in glucocorticoids and nonsteroidal anti-inflammatory drugs ones.

scholarly journals Difficulties in management of patients with systemic lupus erythematosus and antiphospholipid syndrome in combination with melanoma and infiltrative tuberculosis (clinical observations)

2021 ◽  
Vol 15 (4) ◽  
pp. 87-93
Author(s):  
A. A. Shumilova ◽  
T. M. Reshetnyak ◽  
F. A. Cheldieva ◽  
A. M. Lila
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Herpes Zoster ◽  
Cardiovascular Diseases ◽  
Antiphospholipid Syndrome ◽  
Lupus Erythematosus ◽  
Clinical Guidelines ◽  
Malignant Neoplasms ◽  
Systemic Lupus ◽  
Clinical Observations

We present two clinical cases: the first patient had combination of antiphospholipid syndrome (APS) and melanoma, and the second – systemic lupus erythematosus (SLE) and APS, melanoma, infiltrative tuberculosis and Herpes zoster. Managing patients with SLE combined with APS is really challenging. Infections and malignant neoplasms, along with kidney damage and cardiovascular diseases, are a significant cause of death in this cohort of patients. The role of antibodies to phospholipids in the onset of malignancy is still under discussion. The combination of rheumatic diseases with oncological or infectious pathology complicates therapy, limiting the use of drugs, recommended by clinical guidelines.

scholarly journals Netosis in the pathogenesis of antiphospholipid syndrome and systemic lupus erythematosus

2021 ◽  
Vol 15 (5) ◽  
pp. 96-102
Author(s):  
K. S. Nurbaeva ◽  
T. M. Reshetnyak ◽  
A. M. Lila
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Antiphospholipid Syndrome ◽  
Lupus Erythematosus ◽  
Space Form ◽  
Clinical Manifestations ◽  
Immunosuppressive Drugs ◽  
Systemic Lupus ◽  
Extracellular Traps ◽  
Activated Neutrophils

Antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE) are autoimmune diseases. In recent years, APS has been considered as an autoimmune thrombo-inflammatory disease. It has been established that clinical manifestations of APS can persist, progress over time, or debut during an adequate anticoagulant therapy and, in some cases, require administration of immunosuppressive drugs, which indicates the role of autoimmune inflammation in their development. The formation of extracellular neutrophil traps (neutrophil extracellular traps, NETs) is one of the connecting links of inflammation and thrombosis. Netosis is the process by which activated neutrophils in the extracellular space form netlike structures (NETs). This review examines the role of neutrophils and netosis in the pathogenesis of APS and SLE.

Sign in / Sign up

Export Citation Format

Share Document